| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Division of Molecular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121;
Max von Pettenkofer-Institut fur Hygiene und Medizinische Mikrobiologie, Lehrstuhl Virologie, Genzentrum, Ludwig-Maximilians-Universitat Munchen, Munich, Germany; and
GSF Research Center for Environment and Health, Institute of Molecular Immunology, Clinical Cooperation Group, Hemopoietic Stem Cell Transplantation, Munich, Germany
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-inducible protein 10, a CXC
chemokine lacking an ELR motif, was able to reverse the effect of KC on
viral replication. The mutant viruses also showed significantly
reduced reactivation from latently infected mouse splenocytes.
Reinsertion of ORF74 into the mutant virus restored the wild-type
phenotype. Utilizing a viral CXCR2 homologue to enhance replication and
reactivation from latency represents a novel mechanism by which
gammaherpesviruses can subvert the immune
response. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Murine gammaherpesvirus-68 (MHV-68) is a member of the gamma-2 subfamily of herpesviruses and is closely related to the human pathogen Kaposi’s sarcoma-associated herpesvirus (KSHV, human herpesvirus 8) (2, 3, 4). Sequence analysis has shown that the MHV-68 open reading frame 74 (ORF74) encodes a GPCR homologue of the cellular CXCR2 chemokine receptor (2). This gene is conserved in other gamma-2-herpesviruses such as KSHV, herpesvirus samiri, and equine herpesvirus 2 (2, 5, 6, 7, 8) and is, therefore, likely to play an important role in viral pathogenesis and/or immune evasion. The KSHV GPCR has been shown to be constitutively active, although further increases in activity can be achieved by the exogenous addition of CXC chemokines and can induce cell proliferation (7, 9). In both MHV-68 and KSHV, the viral GPCR (vGPCR) is expressed during lytic replication (10, 11, 12). It has been more difficult to detect expression of the vGPCR during latency for either MHV-68 or KSHV. However, using a highly sensitive nested RT-PCR, Wakeling et al. (13) were able to detect expression of MHV-68 GPCR in spleen and lung during viral persistence, whereas Virgin et al. (14) detected the MHV-68 GPCR in latently infected macrophages from B cell-deficient mice.
Since the MHV-68 ORF74 gene has significant sequence homology to the KSHV ORF74 (2), studies on MHV-68 deletion mutants are of considerable interest in delineating the role and significance of this vGPCR.
Recently, the cloning of several herpesviruses, including MHV-68, as infectious bacterial artificial chromosomes (BAC) has been described (15). This system has been useful for the introduction of various types of targeted mutation into the viral genome. In the present study, we used a BAC cloning system, that was described earlier (15), to generate MHV-68 viruses with mutations in the ORF74. Using these mutant viruses, we investigated the role of the vGPCR in MHV-68 replication and reactivation from latency.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The original stock of MHV-68 (clone G2.4) was obtained from Dr. A. A. Nash (University of Edinburgh, Edinburgh, U.K.). The virus was grown in baby hamster kidney cells (BHK-21, CCL10; American Type Culture Collection, Manassas, VA) maintained in Glasgow’s modified Eagle’s medium (Life Technologies, Grand Island, NY) supplemented with 10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin. The BHK-21 cells were infected at a multiplicity of infection (MOI) of 0.01, and virus stocks were prepared when the cytopathic effect was complete, by freezing and thawing the cells twice. Virus titers were determined by plaque assay on NIH 3T3 cells (CRL1658; American Type Culture Collection) grown in DMEM (Life Technologies) supplemented with 10% FCS, 1% L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (complete DMEM). Serial 10-fold dilutions of virus were absorbed onto NIH 3T3 monolayers for 1 h at 37°C and then washed with fresh medium and overlaid with medium containing 1.6% carboxymethylcellulose (CMC). After 6 days, the monolayers were fixed with 10% paraformaldehyde and stained with 0.3% crystal violet solution to determine the number of plaques.
Generation of ORF74 mutants
Recombinant viruses with mutations in the ORF74 were made using MHV-68 cloned as BAC as recently described (15). Two different methods were used to delete regions of the ORF74. The first deletion mutant (ORF74FRT mutant) was generated by "ET-cloning" as described elsewhere (16). To this end, a linear PCR fragment containing a FRT-flanked tetracycline resistance cassette was generated from vector pCP16 (17) using a primer pair that contained 24 nt for amplification of the tetracycline resistance gene and an additional 50 nt homologous to sequences flanking the region to be deleted, corresponding to nucleotide positions 105091–105140 and 105785–105834 (2), respectively. This PCR product was transferred into the MHV-68 BAC by homologous recombination in Escherichia coli strain DH10B already containing the MHV-68 BAC and the plasmid pKD46 (18). The plasmid pKD46 expresses the Red recombinase system under the control of a regulated (L-arabinose-inducible) promoter and mediates the recombination. Successful recombination led to the deletion of nt 105141–105784 of MHV-68. The tetracycline resistance gene was than removed by Flp-mediated recombination as described previously (19). Recombinant BAC plasmids were characterized by restriction enzyme analysis and sequencing.
A second, independent deletion mutant (ORF74DEL mutant) was generated by a two-step replacement procedure as described elsewhere (19, 20). For that purpose, a 3.495-kb SphI fragment of MHV-68 (nucleotide positions 103880–107375) was cloned into the shuttle plasmid pST76K-SR (15). From this fragment, 440 bp of ORF74 were removed using two BsrGI sites (nucleotide positions 105376 and 105816), and the resulting fragment was transferred into the MHV-68 BAC by homologous recombination in E. coli strain DH10B. Recombinant BAC plasmids were characterized by restriction enzyme analysis and sequencing.
An additional mutant with a stop linker inserted in ORF74 (ORF74STOP mutant) was generated by the above-mentioned two-step replacement procedure. For that purpose, a 5.186-kb EcoRI fragment of MHV-68 (nucleotide positions 103164–108350) was cloned into the plasmid pK18 (21). A 16-bp stop linker containing a HpaI site and stop codons in all possible frames (22) was inserted in the MfeI site at nucleotide position 105568 of MHV-68. The resulting EcoRI fragment containing the stop linker was cloned into the shuttle plasmid pST76K-SR and transferred into the MHV-68 BAC by homologous recombination in E. coli strain DH10B. Recombinant BAC plasmids were characterized by restriction enzyme analysis and sequencing.
A revertant BAC plasmid to the ORF74 STOP mutant (ORF74STOP revertant) was generated by the two-step replacement procedure. For that purpose, a 3.495-kb SphI fragment of MHV-68 (nucleotide positions 103880–107375) was cloned into the shuttle plasmid pST76K-SR and electroporated into E. coli strain DH10B that already contained the ORF74 STOP mutant BAC. Recombinant BAC plasmids were characterized by restriction enzyme analysis and sequencing.
Electroporation of 
2–3 µg of the recombinant BAC plasmids into
BHK-21 cells resulted in the reconstitution of recombinant viruses
expressing the gfp gene. To remove the BAC vector sequences,
rat embryonic fibroblasts expressing recombinase Cre (15)
were infected, and viral clones with the BAC vector sequences deleted
were purified by limiting dilution using loss of green fluorescent
protein expression as a screening marker. DNA of all
reconstituted, recombinant viruses was isolated from infected BHK-21
cells and analyzed by restriction enzyme digestion. Successful
mutagenesis was confirmed by Southern blot analysis. The DNA was
transferred onto a Hybond N+ membrane (Amersham,
Arlington Heights, IL). Blots were hybridized overnight with
digoxigenin-labeled probes and developed using the ECL system
(Boehringer Mannheim, Indianapolis, IN) according to the instructions
of the manufacturer.
Replication of the ORF74 mutant viruses in vitro
Single-step and multistep virus growth experiments were conducted to compare the growth kinetics of mutant and revertant viruses to those of the parent virus. A series of replicate cultures of BHK-21 or NIH 3T3 cells was infected separately at a MOI of 1 for single-step and 0.01 for multistep assays. After 1 h of adsorption, the wells were washed with medium. Infected cultures were harvested at successive intervals postinfection, and the amount of infectious virus in the culture was determined by plaque assay on NIH 3T3 cells as described above.
Infectious center assay
The frequency of latently infected cells in mouse splenocyte suspensions was determined by infectious center assay. Spleens were removed from C57BL/6 mice and spleen cell suspensions were prepared using cell strainers (BD Labware, Franklin Lakes, NJ). Splenocytes were infected with MHV-68 at a MOI of 10 for 24 h at 37°C and then plated at various densities (107–105/well) onto monolayers of NIH 3T3 cells in 12-well plates, incubated overnight, and then overlaid with medium containing 1.6% CMC. The cells were cocultured for 5–6 days, and plaques were counted as described above. Parallel cultures were set up using aliquots of 107–105 spleen cells and disrupted using a Tissue-Tearor homogenizer (Fisher, Pittsburgh, PA) to determine the amount of preformed infectious virus.
RT-PCR assays
Total RNA from NIH 3T3 cells infected with viruses was prepared using TRIzol (Life Technologies) as recommended by the manufacturer. The RNA was resuspended in 50 µl of diethyl pyrocarbonate-treated water, quantitated, and treated with DNase (Life Technologies) as recommended by the manufacturer. RNA (2 µg) was reverse transcribed by using the Superscript preamplification system (Life Technologies) for first-strand cDNA synthesis in a total volume of 25 µl, and a no-reverse transcriptase control was conducted in parallel. The primer sequences for the ORF73 genes were 5'-ATCTTTTTGGTGGAGGGGGACC-3' and 5'-ACCGACTACACGCAACACAACC-3'. The primer sequences for the ORF74 genes were 5'-GGATTCCAGATTTGGCGAGC-3' and 5'-AGGTCTCTTGAACCCACCCTAGTC-3'. The primer sequences for the ORF75c genes were 5'-CCTGGTTGGTGACAAGAGAGTTG-3' and 5'-CTGTTATGCGATGGTGGAGACAC-3'. The primer sequences for the M11 genes (Bcl-2 homologue) were 5'-GCAACCCTGATTACAGCCTTC-3' and 5'-CAGAATATATCCTGGGCAACACC-3'. The products were analyzed on 1% agarose gel. The following conditions were used: for ORF73: 94°C for 2 min; 30 cycles of 94°C for 1 min, 58°C for 2 min, and 72°C for 3 min, followed by a 7-min final extension at 72°C. For ORF74 and ORF75c: 94°C for 4 min; 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30s, followed by a 15-min final extension at 72°C.
Real-time quantitative PCR
Quantitation of viral genomes was performed by real-time PCR using the 5700 Sequence Detection System (PE Biosystems, Foster City, CA). This method is based on the continuous optical monitoring of a fluorogenic PCR.
PCR primers for the MHV-68 gp150 gene were used. The upstream and downstream primer sequences were 5'-CAACAATCCCACTACAATTATGCG-3' and 5'-TGCGGGCGTCTTTGTGT-3', respectively. The fluorogenic probe located between the PCR primer was synthesized by PE Biosystems (5'-(VIC)-ACTCTCACCATTTTGGGCCACAGGG-(TAMRA)-3', where VIC is reporter dye and TAMRA is a quencher dye. The sequences of the two primers, as well as that of the probe, were selected from a region that does not share significant homology with other known nucleotide sequences in GenBank.
Statistical analysis
Statistical analysis was performed using Student’s t test.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To analyze the effect of disrupting ORF74 of MHV-68, three
independent mutants were constructed by different methods using MHV-68
cloned as a BAC (15) (Fig. 1
A). A deletion mutant
(ORF74FRT mutant), lacking 644 bp of ORF74, was constructed by
insertion of an FRT-flanked tetracycline resistance gene. After
removing the tetracycline resistance gene by FLP-mediated
recombination, a small residual insert consisting of an FRT site and
some vector sequence is left in the disrupted ORF74 gene. To
control for any effects of this small residual insert, a second
deletion mutant (ORF74DEL mutant), lacking 440 bp of ORF74, was
generated by a two-step replacement procedure which does not leave any
foreign sequence behind. To exclude any effects the deletions
introduced in ORF74 might cause on neighboring genes or regulatory
sequences, a third independent mutant (ORF74STOP mutant) was made by
insertion of a 16-bp stop linker into ORF74. This stop linker was first
described for the construction of HSV-1 mutants (22) and
has recently been used to construct a mutant of ORF72 (v-cyclin) of
MHV-68 (23). To exclude the possibility that observed
effects were due to rearrangements outside ORF74, a revertant of the
ORF74STOP mutant (ORF74STOP revertant) was generated using an unmutated
genomic fragment by a two-step replacement procedure. The structure of
all cloned genomes was verified by restriction enzyme digestion with
different enzymes and by sequencing the site of mutation (data not
shown). Recombinant viruses were reconstituted from all BAC-cloned
genomes, the BAC vector sequences were removed, and the structure of
all recombinant viruses was analyzed by restriction enzyme digestion of
viral DNA and Southern blot (Fig. 1B). Bands of the expected
size were observed, confirming the structure of the mutated viral
genomes.
|
The disruption of the ORF74 might inadvertently disrupt
promoter/enhancer regions of neighboring genes. We used RT-PCR to
confirm that the neighboring ORF73 and ORF75c were transcribed normally
in the mutant viruses. Transcription of the M11 gene, which
is expressed on a bicistronic transcript with ORF74 (13),
was also analyzed. Our previous data showed that all four genes are
expressed during lytic replication of MHV-68 in NIH 3T3 fibroblasts
(S. R. Sarawar and B. J. Lee, unpublished data). NIH
3T3 fibroblasts were infected with the mutant, or wild-type virus, and
the total cellular RNA was recovered. The RNA was briefly treated with
DNase I to remove contaminating viral DNA and was then analyzed by
RT-PCR. As shown in Fig. 2, wild-type
virus yielded a PCR product corresponding to the predicted 759-bp
fragment for ORF74, 362-bp fragment for ORF73, 405-bp fragment for ORF
75c, and 400-bp fragment for M11. The stop mutant virus yielded a PCR
product for ORF74 that was very slightly larger than that of the
wild-type virus (due to the presence of the stop linker), whereas the
two deletion mutants gave PCR products of around 600 bp, confirming the
deletion. The products for the adjacent ORF73,
ORF75c, and M11 genes were present as in
wild-type virus, showing that the mutagenesis of ORF74 did not affect
the transcription of neighboring genes. Control reactions without
reverse transcriptase yielded no bands (data not shown), indicating
that there was no contamination of the RNA preparation with viral
DNA.
|
One-step growth curve experiments were conducted to identify
potential alterations in replication of the mutant viruses in vitro. We
compared replication of wild-type, FRT mutant, DEL mutant, stop mutant,
and revertant viruses in a single round of replication in both NIH 3T3
(Fig. 3A) and BHK-21 cells
(data not shown). There was no difference in viral replication. Similar
results were obtained in multistep growth assays (Fig. 3B)
Furthermore, the plaque sizes were similar for the mutant, revertant,
and wild-type viruses (Fig. 3C). This indicates that ORF74
is not essential for replication of MHV-68 in vitro.
|
Since both KSHV and HVS GPCR have been shown to signal in response
to CXC chemokines (6, 9), we hypothesized that MHV-68
replication might be increased by the exogenous addition of chemokine
ligands such as KC. The latter is a CXC chemokine with an ELR motif and
is a ligand for the cellular CXCR2 chemokine receptor. Clear
differences were observed in viral replication following treatment with
KC (Fig. 4, A–C). Maximal
responses were obtained at a concentration of 10 ng/ml KC (Fig. 4A). The effect of KC on viral replication peaked at 12–24
h after treatment (Fig. 4B). Wild-type virus titers were
significantly higher in the presence, than in the absence, of KC at 12
or 24 h after infection (p < 0.0001, at
each time point). RNase protection assays failed to detect cellular
CXCR2 in either uninfected or MHV-68-infected fibroblasts (data not
shown), suggesting that the effect of KC on viral replication might be
mediated via the vGPCR. This contention was supported by the finding
that KC did not increase the replication of STOP, FRT, or DEL ORF74
mutant viruses. In contrast, replication of the revertant virus was
increased by KC to an extent similar to the wild-type virus, showing
that the lack of response of the mutant virus to KC was due to the
disruption of ORF74 and not to mutations inadvertently introduced
elsewhere in the viral genome. These data show that MHV-68 replication
is enhanced by the CXC chemokine KC and that the vGPCR is required for
this effect.
|
D). Crg-2
(mouse IFN--inducible protein 10 (IP-10)) is a CXC chemokine lacking
an ELR motif which binds to a different cellular receptor from KC and
MIP-2. IP-10 has been shown to function as an inverse agonist for the
KSHV GPCR (39, 40). Crg-2 had no effect on MHV-68
replication when added alone, but was able to significantly reduce the
increase in viral replication induced by KC (p
< 0.01, Fig. 4E). In contrast, RANTES and MCP-1 had no
effect on KC-augmented viral replication (data not shown). Signaling via the MHV-68 GPCR
To investigate the nature of the G proteins coupling with the
MHV-68 CXCR2 homologue, pertussis toxin (100 µg/ml) was added to
virus-infected NIH 3T3 cells in the presence and absence of KC.
Pertussis toxin did not affect KC-enhanced viral replication (Fig. 5A), suggesting that G
proteins of the pertussis toxin-insensitive Gq family rather than Gi/o
proteins, which are generally pertussis-toxin sensitive, were used in
the effects on viral replication mediated via the MHV-68 GPCR.
|
B).
In contrast, replication of the wild-type virus in the absence of added
chemokines or of the ORF74 STOP or DEL mutant viruses in the presence
of KC was unaffected by LY294002 or PD98059 (Fig. 5B). U0126
reduced replication of the wild-type, revertant, and mutant viruses in
the presence of KC to below the level of replication in the absence of
added chemokine (Fig. 5B). The percentage reduction was
16–28% and was statistically significant for the wild-type, STOP
mutant, and revertant (p < 0.01 in each case),
but not for the FRT mutant. A similar small reduction was observed in
the replication of the wild-type virus in the absence of KC (data not
shown). Because both mutant and wild-type viruses were affected and
because the other MEK inhibitor PD98059 did not have the same effect,
it is possible that this reflects a minor nonspecific effect of
U0126.
In summary, the data in Fig. 5B show that the signaling
pathway by which KC stimulates viral replication via the MHV-68 GPCR
involves both MEK and PI3-kinase.
Role of vGPCR in viral reactivation from latency
In addition to its function in chemokine-stimulated viral
replication, the role of the MHV-68 GPCR in the reactivation of latent
virus was examined. Mouse splenocytes were infected in vitro with
mutant, wild-type, or revertant virus at a MOI of 1 for 24 h and
then washed thoroughly with medium. Infected splenocytes were then used
in an infectious center assay, which measures viral reactivation in
culture. Reactivation of latent virus requires intact viable cells.
Therefore, mechanically disrupted splenocytes were used as a control to
detect preformed infectious virus. Cultures using disrupted splenocytes
yielded only low numbers of plaques showing that the majority of
plaques in the infectious center assay were the result of viral
reactivation from latency (data not shown). The frequency of infectious
centers was significantly lower in splenocytes infected with the STOP
mutant virus than in those infected with either the wild-type or
revertant virus (Fig. 6A,
p < 0.0001). Similar results were obtained with the
FRT and DEL mutants (p < 0.0001, in each
case). In contrast, the level of viral genomes, determined by real-time
quantitative PCR, was similar in splenocytes infected by wild-type and
mutant viruses (Fig. 6B). This suggests that the mutant
virus is able to establish latency in splenocytes to the same extent as
the wild-type virus, but reactivation from latency is impaired.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Members of the gamma-2-herpesvirus subfamily, on the other hand, encode
CXC chemokine receptor homologues (2, 5, 6, 7, 8). These vGPCR
are encoded by ORF74 and are conserved in all members of the
gamma-2-herpesvirus subfamily that have been sequenced to date,
suggesting that they play an important role in viral growth and/or
immune evasion. Since the gamma-2-herpesvirus family includes the KSHV
(HHV8), which has been implicated in the induction of disease in humans
(7, 35, 36), it is especially important to understand the
function of these viral genes. However, suitable ORF74 mutant viruses
and culture systems for exploring the effect of the vGPCR on KSHV
replication are not currently available. Therefore, we investigated the
role of the vGPCR in vitro using a mouse -2 herpesvirus.
The approach that we chose was to construct MHV-68 mutants
lacking functional vGPCR. The vGPCR of both MHV-68 and KSHV
(Refs. 11, 12, 13, 37, 38 ; Fig. 2) are expressed during lytic
replication. Expression of the MHV-68 GPCR during persistence has also
been reported (13, 14).
We found that CXC chemokines, such as KC, enhanced MHV-68 replication in permissive fibroblasts by a mechanism that was dependent on the vGPCR. Thus, stimulation of viral replication by KC was significantly impaired in mutant viruses lacking the viral chemokine receptor. Another striking feature of the ORF74 mutant virus was its significantly reduced ability to reactivate from latently infected splenocytes. Several mutants, constructed using different strategies, all showed the same phenotype, both in terms of reactivation from latency and the replicative response to KC. Thus, it is unlikely that the observed phenotype was an artifact caused by the method of construction of the mutants. Reinsertion of the ORF74 into the mutant virus (construction of a revertant virus) restored the wild-type phenotype, again showing that the observed properties of the mutant were indeed due to the lack of the ORF74 gene product and not due to a secondary mutation that had occurred elsewhere in the genome. The fact that neighboring genes were expressed normally showed that mutation of the ORF74 gene had not inadvertently affected their transcription.
The CC chemokines RANTES and MCP-1 did not affect MHV-68 replication. Neither did the CXC chemokine crg-2 (mouse IP-10), which lacks an ELR motif. Therefore, only the CXC chemokines with ELR motifs appear to meet the structural requirements for binding and/or signaling through the MHV-68 GPCR that are necessary for the increased viral replication. Although crg-2 (mouse IP-10) did not affect viral replication alone, it was able to inhibit the increase in viral replication induced by KC. This is reminiscent of the ability of IP-10 to function as an inverse agonist for signaling of the KSHV GPCR (39, 40). Thus, our data confirm and extend previous findings on the inhibitory effect of IP-10.
The stimulation of viral replication via the vGPCR was insensitive to pertussis toxin, indicating that the G protein used was more likely to be Gq than the pertussis toxin-sensitive Gi/o proteins. Previous studies have documented signaling of the KSHV GPCR via both pertussis toxin-sensitive and -insensitive pathways, depending on the cell type (7, 40, 41). The increase in viral replication induced by KC was sensitive to specific inhibitors of both PI3-kinase and MEK, showing that both of these kinases were involved in signaling via the MHV-68 GPCR. Again, this parallels a reported signaling pathway for the KSHV GPCR (42). Interestingly, it has recently been reported that, in mice expressing the KSHV GPCR as a transgene, activation of the receptor by chemokines is necessary for its tumorigenic effect in vivo (43).
The KSHV GPCR can signal constitutively, although its activity can be further increased by CXC chemokines (7, 9). In the case of MHV-68, we do not know whether the GPCR signals constitutively, although it does appear to respond to CXC chemokine ligands. Our studies confirm the published work on chemokine stimulation of signaling via a gammaherpesvirus GPCR and extend these findings to show an effect on viral replication. The general lack of effect of PI3-kinase and MEK kinase inhibitors on the basal replication suggests that the signals via these pathways that affect viral replication are not constitutive. However, this does not rule out the possibility that the MHV-68 GPCR signals constitutively via other pathways. Furthermore, the constitutive activity of the KSHV GPCR depends on the cell type in which it is expressed (41).
The stimulation of viral replication by CXC chemokines in vitro was tested in permissive fibroblasts and a moderate enhancement was seen. Nevertheless, this enhancement was highly significant, was specific for CXC chemokines with ELR motifs, and could be blocked by highly specific inhibitors of both PI3-kinase and MEK. In vivo, macrophages, B cells, dendritic cells, and lung epithelial cells have been shown to harbor MHV-68. Therefore, it is possible that in vivo the degree of stimulation of viral replication via the MHV-68 GPCR may differ from that observed in vitro dependent on the infected cell type.
One of the most interesting features of the MHV-68 GPCR revealed by these studies was its role in viral reactivation from latency. Thus, reactivation of ORF74 mutants from latently infected splenocytes was significantly impaired. This appeared to reflect a problem with reactivation rather than with viral entry into the cells, since real-time quantitative PCR showed that the levels of viral genome in splenocytes were similar for wild-type and mutant viruses.
Signaling via the KSHV GPCR has been shown to differ from that via its
cellular counterpart (7, 41). We do not know whether the
same applies to the MHV-68 GPCR and its cellular counterpart, mCXCR2,
or whether chemokines can stimulate viral replication via the cellular
receptor. We were unable to detect expression of the cellular receptor
in cultured fibroblasts. However, preliminary results suggest that
there is no difference in MHV-68 replication in
CXCR2+/+ and CXCR2-/-
mice (B. J. Lee and S. R. Sarawar, unpublished data). MHV-68
has been shown to establish latency in splenic macrophages, dendritic
cells, and B cells (44, 45, 46, 47). Thus, both
CXCR2+ (macrophages and dendritic cells) and
CXCR2- (B cells) harbor MHV-68 in splenocyte
cultures. As shown in Fig. 6, reactivation of the viral CXCR2 mutants
from latently infected splenocytes was dramatically reduced compared
with that of the wild-type virus. We have also seen the same effect in
splenocyte cultures from B cell-deficient mice (B. J. Lee and
S. R. Sarawar, unpublished data). Hence, even when the cellular
CXCR2 is present on the infected cell types, the viral chemokine
receptor still has a significant effect.
Our observations suggest that herpesvirus vGPCR may play a role in
viral replication and reactivation from latency in vivo. This role may
be more prominent in immunocompromised individuals. However, this does
not exclude the possibility that the vGPCR plays additional roles in
viral dissemination and immune evasion, as do the CC chemokine receptor
homologues in betaherpesviruses. We are currently examining the
pathogenesis of the mutant viruses in both normal and
immunocompromised mice.
We conclude that the gammaherpesvirus vGPCR modulates both viral replication and reactivation from latency and that this represents a novel mechanism by which gamma-2-herpesviruses can subvert components of the immune system.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 This is publication number 496 from the La Jolla Institute for Allergy and Immmunology.
3 S.R.S. and H.A. made equal contributions to this study.
4 Address correspondence and reprint requests to Dr. Heiko Adler, GSF Research Center for Environment and Health, Institute of Molecular Immunology, Clinical Cooperation Group, Hemopoietic Stem Cell Transplantation, Marchioninistrasse 25, D-81377, Munich, Germany. E-mail address: h.adler{at}gsf.de; or Dr. Sally R. Sarawar, Division of Molecular Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121. E-mail address: ssarawar{at}liai.org
5 Abbreviations used in this paper: GPCR, G protein-coupled receptor; MHV-68, murine gammaherpesvirus 68; KSHV, Kaposi’s sarcoma-associated herpesvirus; ORF, open reading frame; vGPCR, viral GPCR; BAC, bacterial artificial chromosome; MOI, multiplicity of infection; MIP-2, macrophage-inflammatory protein 2; MCP-1, monocyte chemoattractant protein 1; IP-10, IFN--inducible protein 10; MEK, mitogen-activated protein/extracellular signal-regulated kinase; PI3-kinase, phosphatidylinositol 3-kinase; CMC, carboxymethylcellulose.
Received for publication July 18, 2002. Accepted for publication October 29, 2002.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
herpesvirus 68. J. Virol. 71:5894.
herpesviruses, Epstein-Barr virus and herpesvirus saimiri. J. Gen. Virol. 71:1365. herpesvirus 68 reactivates the complete lytic cycle from latency. J. Virol. 74:3659. herpesvirus-68 transcription during lytic and latent infection. J. Gen. Virol. 80:75.[Abstract]
herpesvirus 68 ORF74 product: a novel oncogenic G protein-coupled receptor. J. Gen. Virol. 82:1187. herpesvirus
68 genome are transcriptionally active in latently infected mice.
J. Virol. 73:2321.
herpesvirus 68 genome as an infectious bacterial artificial chromosome. J. Virol. 74:6964. herpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. J. Virol. 75:5692. herpesvirus 68 v-cyclin is a critical regulator of reactivation from latency. J. Virol. 74:7451.
chemokine receptor. J Biol. Chem. 269:28539. chemokine receptor. J. Immunol. 164:2396. herpesvirus 68 gene expression following infection of murine cells in culture and in mice. J. Virol. 75:4955.-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. J. Exp. Med. 188:405.
. Cancer Res. 60:4873. herpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J. Gen. Virol. 73:3275. herpesvirus 68 in peritoneal cells. J. Virol. 73:3273. herpesvirus persistence. J. Exp. Med. 187:1941. herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J. Immunol. 165:1075.This article has been cited by other articles:
|
|
 |
|
  R. M. Melnychuk, P. Smith, C. N. Kreklywich, F. Ruchti, J. Vomaske, L. Hall, L. Loh, J. A. Nelson, S. L. Orloff, and D. N. Streblow Mouse Cytomegalovirus M33 Is Necessary and Sufficient in Virus-Induced Vascular Smooth Muscle Cell Migration J. Virol., August 15, 2005; 79(16): 10788 - 10795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Rosenkilde, T. N. Kledal, and T. W. Schwartz High Constitutive Activity of a Virus-Encoded Seven Transmembrane Receptor in the Absence of the Conserved DRY Motif (Asp-Arg-Tyr) in Transmembrane Helix 3 Mol. Pharmacol., July 1, 2005; 68(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. May, H. M. Coleman, J. M. Boname, and P. G. Stevenson Murine gammaherpesvirus-68 ORF28 encodes a non-essential virion glycoprotein J. Gen. Virol., April 1, 2005; 86(4): 919 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Paulsen, M. M. Rosenkilde, J. Eugen-Olsen, and T. N. Kledal Epstein-Barr Virus-Encoded BILF1 Is a Constitutively Active G Protein-Coupled Receptor J. Virol., January 1, 2005; 79(1): 536 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Rosenkilde, K. A. McLean, P. J. Holst, and T. W. Schwartz The CXC Chemokine Receptor Encoded by Herpesvirus saimiri, ECRF3, Shows Ligand-regulated Signaling through Gi, Gq, and G12/13 Proteins but Constitutive Signaling Only through Gi and G12/13 Proteins J. Biol. Chem., July 30, 2004; 279(31): 32524 - 32533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Verzijl, C. P. Fitzsimons, M. van Dijk, J. P. Stewart, H. Timmerman, M. J. Smit, and R. Leurs Differential Activation of Murine Herpesvirus 68- and Kaposi's Sarcoma-Associated Herpesvirus-Encoded ORF74 G Protein-Coupled Receptors by Human and Murine Chemokines J. Virol., April 1, 2004; 78(7): 3343 - 3351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Liu, G. Sandford, G. Fei, and J. Nicholas G{alpha} Protein Selectivity Determinant Specified by a Viral Chemokine Receptor-Conserved Region in the C Tail of the Human Herpesvirus 8 G Protein-Coupled Receptor J. Virol., March 1, 2004; 78(5): 2460 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. SODHI, S. MONTANER, and J. S. GUTKIND Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? FASEB J, March 1, 2004; 18(3): 422 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Elsawa and K. L. Bost Murine {gamma}-Herpesvirus-68-Induced IL-12 Contributes to the Control of Latent Viral Burden, but Also Contributes to Viral-Mediated Leukocytosis J. Immunol., January 1, 2004; 172(1): 516 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fowler, S. Marques, J. P. Simas, and S. Efstathiou ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency J. Gen. Virol., December 1, 2003; 84(12): 3405 - 3416. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||
